PRL Stock Overview
Pierrel S.p.A. engages in the development, production, registration, and licensing of synthetic drugs and medical devices for the oral health sector worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Pierrel S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.75 |
| 52 Week High | €5.19 |
| 52 Week Low | €1.50 |
| Beta | 0.47 |
| 1 Month Change | 0.29% |
| 3 Month Change | 0.87% |
| 1 Year Change | -61.86% |
| 3 Year Change | -59.42% |
| 5 Year Change | -54.68% |
| Change since IPO | -98.82% |
Recent News & Updates
Recent updates
We Think Pierrel (BIT:PRL) Can Stay On Top Of Its Debt
May 26
Does Pierrel (BIT:PRL) Have A Healthy Balance Sheet?
Aug 11Here's Why Pierrel (BIT:PRL) Has A Meaningful Debt Burden
Apr 05Introducing Pierrel (BIT:PRL), A Stock That Climbed 76% In The Last Year
Mar 10Calculating The Fair Value Of Pierrel S.p.A. (BIT:PRL)
Feb 10
How Is Pierrel's (BIT:PRL) CEO Paid Relative To Peers?
Dec 30These 4 Measures Indicate That Pierrel (BIT:PRL) Is Using Debt Extensively
Dec 01Shareholder Returns
| PRL | IT Pharmaceuticals | IT Market | |
|---|---|---|---|
| 7D | 0.6% | 2.3% | 1.4% |
| 1Y | -61.9% | 7.5% | 20.5% |
Return vs Industry: PRL underperformed the Italian Pharmaceuticals industry which returned 7.2% over the past year.
Return vs Market: PRL underperformed the Italian Market which returned 11.8% over the past year.
Price Volatility
| PRL volatility | |
|---|---|
| PRL Average Weekly Movement | 0.6% |
| Pharmaceuticals Industry Average Movement | 4.8% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in IT Market | 7.5% |
| 10% least volatile stocks in IT Market | 2.7% |
Stable Share Price: PRL has not had significant price volatility in the past 3 months.
Volatility Over Time: PRL's weekly volatility has decreased from 7% to 1% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1948 | 105 | Fulvio Citaredo | www.pierrelgroup.com |
Pierrel S.p.A. engages in the development, production, registration, and licensing of synthetic drugs and medical devices for the oral health sector worldwide. It develops and markets dental anesthesia drugs under the Orabloc brand. The company also offers Goccles, a device for screening of the oral cavity.
Pierrel S.p.A. Fundamentals Summary
| PRL fundamental statistics | |
|---|---|
| Market cap | €95.86m |
| Earnings (TTM) | €3.11m |
| Revenue (TTM) | €26.96m |
30.8x
P/E Ratio3.6x
P/S RatioIs PRL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRL income statement (TTM) | |
|---|---|
| Revenue | €26.96m |
| Cost of Revenue | €13.35m |
| Gross Profit | €13.61m |
| Other Expenses | €10.50m |
| Earnings | €3.11m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.057 |
| Gross Margin | 50.48% |
| Net Profit Margin | 11.53% |
| Debt/Equity Ratio | 109.7% |
How did PRL perform over the long term?
See historical performance and comparison